

### Scott R. Burger, MD – Expert Witness Experience

Supported parties are underlined.

- **Yourway** v. Vincerex – contract dispute  
Gordon Rees Scully Mansukhani, November 2025-April 2026
  - Testified in deposition and in jury trial
  - Background research, wrote one expert witness report
  - Guidance for counsel on regulatory requirements and industry practices for shipping GMP cell banks
  - Identified documents for discovery, advised on lines of argument, questions for depositions, comments on transcripts of opposing witness depositions
  
- **Lieurance and Lieurance** v. Elutia and DCI Donor Services – personal injury  
Erskine & Blackburn, Onstad Law Firm, May 2025-February 2026
  - Testified in deposition
  - Background research, wrote one expert witness report
  - Guidance for counsel on regulatory requirements and industry standards for donor eligibility determination
  - Identified documents for discovery, advised on lines of argument, questions for depositions, comments on transcripts of opposing witness depositions
  
- Rocket Pharmaceuticals v. **Lexeo Therapeutics** – gene therapy trade secret dispute  
Sullivan & Cromwell, April 2025-June 2025
  - Testified in deposition
  - Background research, wrote expert witness report
  - Guidance for counsel on gene therapy for arrhythmogenic cardiomyopathy
  - Identified documents for discovery, advised on lines of argument, comments on transcripts of opposing witness depositions
  
- **Mueller** v. Elutia (Aziyo Biologics), Medtronic Sofamor Danek, Spinalgraft Technologies, DCI Donor Services, and New Mexico Donor Services – personal injury  
Smouse & Mason, October 2024-March 2025
  - Background research, wrote expert witness report
  - Guidance for counsel on regulatory requirements and industry standards for donor eligibility determination
  - Identified documents for discovery, advised on lines of argument, questions for depositions
  - Comments on transcript of opposing witness deposition
  
- Multiple plaintiffs v. **Blue Cross Blue Shield of Michigan**  
Dickinson Wright, November 2024-December 2024
  - Background research, wrote expert witness report
  - Guidance for counsel on use of fetal-derived cells in testing pharmaceuticals

- Memorial Sloan Kettering Cancer Center and **Eureka Therapeutics** v. Juno Therapeutics – contract dispute  
Susman Godfrey. April 2024
  - Background research, wrote rebuttal of opposing expert witness report
  
- **Lyell Immunopharma** v. PACT Pharma – contract dispute  
Sidley Austin, September 2021-April 2022
  - Testified in deposition and before tribunal
  - Background research, wrote three expert witness reports and rebuttals of opposing expert witness reports
  - Guidance for counsel on scientific and technical aspects of cell and gene therapy
  - Identified documents for discovery, advised on lines of argument, questions for depositions
  - Comments on transcripts of opposing witness depositions
  
- **University of North Carolina** v. Vesta Therapeutics – contract dispute  
Robinson Bradshaw and University of North Carolina at Chapel Hill general counsel, January 2021-March 2023
  - Background research, wrote three expert witness reports and rebuttals of opposing expert witness reports
  - Guidance for counsel on stem cells, cell therapy product development, clinical trials, and regulatory pathway
  - Advised on deposition questions
  
- Restem v. **Jadi Cell** – stem cell patent dispute  
Thorpe North & Western, December 2021-December 2022
  - Testified in deposition
  - Reviewed and researched patents and related publications. Wrote expert witness reports including rebuttal of opposing expert witness
  - Guidance for counsel on stem cells and cell therapy product development
  - Identified documents for discovery, advised on lines of argument and deposition questions
  
- **Mitsubishi Tanabe Pharma Corporation** v. Kolon Life Science – contract dispute  
Sidley Austin, June 2019-February 2020
  - Testified before tribunal
  - Background research, wrote three expert witness reports and rebuttals of opposing expert witness reports
  - Guidance for counsel on development and clinical trials of cell and gene therapy products
  - Advised on lines of argument and deposition questions, comments on transcripts of opposing witness depositions

- **Atara Biotherapeutics** v. Allogene Therapeutics –trademark case  
Sheppard Mullin, June 2020-September 2020
  - Testified in deposition
  - Background research, wrote two expert witness reports including rebuttal of opposing expert witness
  - Advised on lines of argument and deposition questions
  - Comments on transcript of opposing expert witness deposition
  
- **MediciNova** v. Genzyme Corporation - gene therapy patent case  
Sheppard Mullin, August 2017-June 2019
  - Testified in two depositions
  - Testified in court twice (tutorials on gene therapy for judge, by request)
  - Wrote three expert witness reports and rebuttals of opposing expert witness
  - Reviewed and researched patents, contracts, and supporting documents
  - Guidance on gene therapy development and manufacturing, advice on lines of argument

**Curriculum Vitae**  
**Scott R. Burger, M.D.**

- Consultant on manufacturing, regulatory, and strategic aspects of cell and gene therapy products. Over 30 years of experience developing advanced therapies. Have served over 200 companies, from biotech startups to Big Pharma, in North America, Europe, Asia, and Australia, working on products from preclinical development through Phase I/II/III, and commercialization.
- Directed or consulted on process development, GMP manufacturing, clinical trials, and CMC regulatory aspects of CAR T-cell, TCR-T cell, TIL, NK, and DC immunotherapies; gene-edited cell therapy products, AAV and AV gene therapy products; stem cell- and somatic cell-based regenerative medicine products including placental and umbilical cord MSCs, iPSCs, HSCs, retinal stem cells.
- Deep knowledge and extensive experience with closed-system processing, scale out/scale up, automation, potency testing, and comparability.
- Established regulatory expert in cell and gene therapy, has consulted on preparation of over 100 regulatory submissions for cell therapy or gene therapy products at all stages of development. Numerous productive interactions with FDA-CBER Office of Therapeutic Products and its predecessors, Office of Tissues and Advanced Therapies (OTAT) and Office of Cellular, Tissue and Gene Therapies (OCTGT).
- Extensive experience performing technical and regulatory due diligence for investment firms and Big Pharma. and providing guidance on investor expectations to cell and gene therapy startups seeking funding.
- Experienced expert witness in cases involving cell and gene therapy intellectual property, commercialization, FDA regulatory affairs, and GMP compliance.

**Present Position**

Founder, Principal  
Advanced Cell & Gene Therapy, LLC  
105 Highgrove Drive  
Chapel Hill, North Carolina 27516-8376

+1 (919) 414-6947  
celltherapy@ac-gt.com  
[www.ac-gt.com](http://www.ac-gt.com)

**Education and Training**

1983	B.S., cum laude, distinctive honors in Biology, Tulane University, New Orleans, LA
1988	M.D., University of Pennsylvania School of Medicine, Philadelphia, PA
7/89-6/94	Laboratory Medicine Residency, Washington University Medical Center, St. Louis, MO
7/93-6/94	Transfusion Medicine Fellowship, Washington University Medical Center, St. Louis, MO

## **Professional Experience**

- 5/02-Present Principal, Advanced Cell & Gene Therapy, LLC, Chapel Hill, NC
- 4/03-4/08 Adjunct Associate Professor, Department of Pathology and Laboratory Medicine  
School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC
- 5/01-5/02 Vice President, Research and Development  
Merix Bioscience, Inc., Durham, NC
- 12/00-5/01 Medical Director, Minnesota Molecular and Cellular Therapeutics Facility  
University of Minnesota Academic Health Center, Minneapolis, MN
- 7/94-12/00 Director, Cell Therapy Clinical Laboratory; Assistant Medical Director, Blood Bank  
University of Minnesota Medical Center, Minneapolis, MN
- 7/94-5/01 Physician Assistant Professor, Department of Laboratory Medicine and Pathology  
Associate Member, Graduate Faculty in Clinical Laboratory Science (1997-2001)  
University of Minnesota Medical School, Minneapolis, MN
- Assistant Medical Director, North Central American Red Cross, St. Paul, MN

## **Honors and Awards**

- 1983 Distinctive honors in Biology, Tulane University
- 1989 Young Investigator Award with Distinction, Academy of Clinical Laboratory  
Physicians and Scientists
- 1991 Young Investigator Award, Academy of Clinical Laboratory Physicians and  
Scientists
- 1993-94 Chief Resident, Department of Laboratory Medicine, Barnes Hospital, Washington  
University Medical Center
- 1999 Scholar Award, National Blood Foundation
- 2000 Best Abstract Award, International Society for Hematotherapy and Graft  
Engineering

## **Medical Licensure and Board Certification**

- 1990 Diplomate, National Board of Medical Examiners, #341174
- 11/19/97 Diplomate in Clinical Pathology, American Board of Pathology, #97-650
- 9/94-02 State of Minnesota Medical License #37314

## **Editorial Boards, Committees**

American Association of Blood Banks (AABB)

Somatic Cell Therapy Standards Program Unit (8/2002-12/2004)

International Society for Cellular Therapy (ISCT)

Gene Therapy Committee (6/1995-5/2004), Legal and Regulatory Affairs Committee (5/2003-2008), Commercialization Committee (8/2006-4/2016), Product Development and Manufacturing Committee (8/2010-present), Global Regulatory Perspectives Workshop Organizing Committee (1/2008-present; co-chair, 10/2007-5/2012)

Advisory Board (5/2000-5/2002), Executive Committee (5/2001-8/2005)

Editorial Board, Cytotherapy (5/2002-5/2005)

Editorial Board, Telegraft (1/1999-8/2006; editor, 5/2001-8/2005)

U.S. Pharmacopeia (USP)

Cell, Gene, and Tissue Therapies Expert Committee (4/2005-5/2010)

Williamsburg BioProcessing Foundation

Editorial Board, BioProcessing, (4/2002-6/2004)

## **Advisory Boards (excludes non-disclosable board participation)**

BioLife Solutions, Seattle, Washington

Scientific Advisory Board (9/2007-present)

Carolina BioOncology Institute – BioCytics

Scientific Advisory Board (6/2022-present)

BioCision, San Rafael, California

Scientific Advisory Board (11/2013-11/2015)

Longevity Therapeutics, Chicago, Illinois

Scientific Advisory Board (12/2011-12/2014)

HemaCare Corporation, Los Angeles, California

Chairman, Scientific Advisory Board (4/2011-4/2016)

Regenerative Medicine Foundation, Winston-Salem, North Carolina

Scientific Advisory Council (7/2010-7/2012)

Opexa Therapeutics, The Woodlands, Texas

Clinical and Scientific Advisory Boards (4/2005-4/2008)

Johnson & Johnson Stem Cell Internal Venture, Radnor, Pennsylvania

Scientific Advisory Board (4/2004-4/2008)

Johnson & Johnson Pharmaceutical R&D – T Cell Immunotherapy, La Jolla, California

Scientific Advisory Board (10/2006-7/2007)

Schering AG, Berlin, Germany

Spheramine Scientific Advisory Board (7/2003-7/2006)

BioE, Inc., White Bear Lake, Minnesota

Scientific Advisory Board (9/2002-12/2004)

## **Reviewer - Journals, Grants, Abstracts**

BioProcessing

Bone Marrow Transplantation

Cytherapy

Nature Reviews Drug Discovery

Transfusion

American Society of Hematology (ASH)

California Institute for Regenerative Medicine (CIRM)

Defense Medical Research and Development Program (DMRDP)

International Society for Cellular Therapy (ISCT)

National Heart, Lung, and Blood Institute-National Institutes of Health (NHLBI-NIH)

National Marrow Donor Program (NMDP)

## **Professional Societies and Organizations**

International Society for Cellular Therapy (ISCT)

## **Military Service**

1/22/88 U.S. Navy, honorable discharge

## **Patents**

9/21/99 Infusible-grade short-term cell storage medium for mononuclear cells. Patent #5,955,257. Scott R. Burger, Allison Hubel, Jeffrey McCullough.

8/21/01 Infusible grade short-term cell storage medium. Patent #6,277,557. Scott R. Burger, Allison Hubel, Jeffrey McCullough.

## **Invited Presentations (selected from over 100)**

5/01 Translational Development of Novel Cell Therapies. Somatic Cell Therapy meeting and workshop, Captiva Island, FL.

12/01 Translational Development of Cellular Therapies Workshop. International Society for Hematotherapy and Graft Engineering GMP 2001 workshop, Orlando, FL.

5/02 Gene Transfer to Dendritic Cells - Gene Therapy Workshop. International Society for Cellular Therapy (ISCT) 2002 annual meeting, Barcelona, Spain.

9/02 Translational Development and GMP Production of Novel Cell and Gene Therapies. Kyoto University Hospital, Kyoto, Japan.

9/02 Translational Development and GMP Production of Advanced Cell and Gene Therapies. Translational research symposium, Japanese Society of Hematology-Japanese Society of Clinical Hematology 2002 joint meeting, Yokohama, Japan.

**Invited Presentations, selected (continued)**

- 11/02      Advanced Cellular Therapies - Translational Development and GMP Production. Scientific symposium, International Society for Pharmaceutical Engineering 2002 annual meeting, Lake Buena Vista, FL.
- 6/03      Advances in Cellular Immunotherapy. Georgetown University Medical Center, Current Topics in Histo compatibility and Transplantation audioconference.
- 4/04      Advanced Cellular Therapies - Development, GMP Manufacturing, and Product Characterization. Cytonet workshop, Heidelberg, Germany.
- 5/04      Cell and Gene Therapy Process Development. Educational Session, ISCT 2004 annual meeting, Dublin, Ireland.
- 6/04      Enabling Commercialization of Clinical Cell and Gene Therapies: Challenges and Strategies. Regenerate 2004, Seattle, WA.
- 6/04      Cell and Gene Therapy: Challenges and Strategies for an Emerging Industry. BioProcessing Asia-Pacific 2004, Sydney, Australia.
- 12/04     Manufacturing Process: Strategies for Cell Therapy Products. DIA/EMEA Joint Meeting on Gene Therapy and Cell Therapy Products, London, UK.
- 1/05      Commercialization of Cell and Gene Therapy Products: When and How? Phacilitate Cell and Gene Therapy Forum, Washington, DC.
- 2/05      Strategies for Manufacturing Cell Therapy Products. Johnson & Johnson Cell Therapy and Regenerative Medicine Task Force, New Brunswick, NJ
- 6/05      Regulatory Pathway for Cell Therapy Products. Stem Cells for Treatment of Neurological Diseases, BIO 2005 annual meeting, Philadelphia, PA.
- 1/06      Options for Manufacturing Cell Therapy Products. Speaker and session chair, Phacilitate Cell & Gene Therapy Forum 2006, Baltimore, MD.
- 2/06      Manufacturing Cell and Gene Therapy Products. Biomanufacturing Workshop, Institute of Bioengineering and Bioscience, Center for the Engineering of Living Tissues, Georgia Institute of Technology/Emory University, Atlanta, GA.
- 5/06      Cell Therapy Product Characterization. Technical Session, ISCT 2006 annual meeting, Berlin, Germany.
- 9/06      Translational Development: From Bench, to Clinic, to Commercial Manufacture. IBC Life Sciences Gene Therapy conference, London, UK.
- 1/07      Overcoming Comparability and Scale-up Challenges in Cell Therapy and Tissue Engineered Product Commercialization. Phacilitate Cell & Gene Therapy Forum 2007, Baltimore, MD.
- 6/07      Developing Stem Cell-Based Therapies - Characterization and Manufacturing. DIA 2007 annual meeting, Atlanta, GA.

**Invited Presentations, selected (continued)**

- 6/07 New Approaches to Product Characterization. Technical Session, ISCT 2007 annual meeting, Sydney, Australia.
- 10/07 Compliance with GTPs/GMPs in Manufacturing Cell and Gene Therapy Products (I). Design, Operation and Management of GTP/GMP Cell Engineering Facilities (II). 2007 International Symposium on Regulation of Human Cell and Tissue-Based Products, Bureau of Food and Drug Analysis, Taipei, Taiwan.
- 10/07 Contract Manufacturing of Cell Therapy Products - Pros, Cons, and Strategies for Success. Industry Symposium, 3<sup>rd</sup> World Congress on Regenerative Medicine, Leipzig, Germany.
- 1/08 Managing Change and Assuring Comparability Throughout Clinical Development. Phacilitate Cell & Gene Therapy Forum 2008, Washington, DC.
- 1/09 Due Diligence for Cell and Gene Therapy. Phacilitate Cell & Gene Therapy Forum 2009, Washington, DC.
- 11/09 Cell/Gene/Tissue-based Therapies: Manufacturing and Characterization. Cell Systems Science Group, National Institute of Standards and Technology, Gaithersburg, MD.
- 1/10 Cell and Gene Therapy Commercialization: Cost Control, Risk Management. Phacilitate Cell & Gene Therapy Forum 2010, Washington, DC.
- 6/10 US Regulatory Requirements for Gene Therapy INDs and BLAs. DIA 2010 annual meeting, Washington, DC.
- 10/10 Pharma's Growing Investment in Regenerative Medicine: Effective Strategic Partnerships. World Stem Cell Summit, Detroit, MI.
- 10/10 Current Regulation of HCT-Ps and Tissue Banks in US and Europe (I). Developments in Cellular Therapy in the US and Europe (II). Manufacturing Cell Therapy Products - Phase II to Commercialization (III). Cell Therapy Product Development: Case Study (IV). 2010 Taipei International Symposium on Human Cell and Tissue-based Products and Tissue Banks, Taipei, Taiwan.
- 12/10 Characterizing ATMPs: Developing Potency Assays and Performing Comparability Studies. Informa Cell Therapy Workshop, London, UK.
- 12/10 Regulation of Cell and Tissue Therapy Products: Europe and Asia. TERMIS North America 2010 annual meeting, Orlando, FL.
- 1/11 Global Regulatory Update (speaker and session chairman). Phacilitate Cell & Gene Therapy Forum 2011, Washington, DC.
- 5/11 US FDA Expectations for Potency Testing of Cell Therapy Products (speaker). Cell Characterization, Potency, and Comparability Studies (session chairman). ISCT 2011 annual meeting, Rotterdam, Netherlands.

**Invited Presentations, selected (continued)**

- 10/11 Global Regulatory Issues in Cell Therapy (speaker and session chair). Asian Cellular Therapy Organization (ACTO) 2011 annual meeting, Miyazaki, Japan.
- 11/11 Potency Testing. ISCT webinar.
- 12/11 Due Diligence for Cell Therapy Products. Informa Cell Therapy Manufacturing Europe, Brussels, Belgium.
- 1/12 Building the Characterization Package Throughout Product Development. Phacilitate Cell & Gene Therapy Forum 2012, Washington, DC.
- 12/12 Roadblocks to Translation - Effective Characterization and Potency Testing (speaker and session chair). World Stem Cell Summit 2012, West Palm Beach, FL.
- 6/13 Potency Assay Development for Cell Therapy Products. FDA Cell Therapy Working Group, Office of Cellular, Tissue and Gene Therapies, Rockville, MD.
- 11/13 Manufacturing and Regulatory Considerations for Cell and Gene Therapy Products. TERMIS-Americas, Atlanta, GA.
- 6/14 Cell Therapy. USP Global Education and Training Webinar.
- 12/14 Demonstrating Comparability: Mitigating Risk of Process Changes in Preclinical and Clinical Development. Informa Cell Therapy Manufacturing Conference, Brussels, Belgium.
- 2/16 Raw Materials for Cell Therapy Products: Regulatory and Manufacturing Considerations. Genetic Engineering & Biotechnology News (GEN) webinar.
- 8/16 Comparability: Mitigating Risk of Manufacturing Process Changes. CHI Bioprocessing Summit, Boston MA.
- 10/16 Process Development and Validation for GMP Manufacturing of ATMPs. Taiwan FDA-TPDA ATMP GMP Workshop, Taipei, Taiwan.
- 1/17 Demonstrating Comparability in Manufacturing Cell and Gene Therapy Products. Phacilitate Cell & Gene Therapy World 2017, Miami FL.
- 5/18 Regulatory Expectations for Manufacturing Control Strategy. ISCT Annual Meeting, Montreal, Canada.
- 12/19 Navigating the Regulatory Pathway for Cell and Gene Therapy Products: Strategies for Successful Cell & Gene Therapy BLA Submissions. CenterWatch/FDAnews webinar.
- 7/20 Demonstrating Comparability in Manufacturing Cell and Gene Therapy Products. FDAnews webinar.
- 8/20 Apheresis Collection for Cell and Gene Therapy Manufacturing. CHI Bioprocessing Summit, Boston, MA.

**Invited Presentations, selected (continued)**

- 10/20 Starting Material Standardization for Autologous and Allogeneic Cell Therapies. Informa Cell & Gene Therapy Bioprocessing & Commercialization, Boston, MA.
- 10/21 Raw Materials for Cell and Gene Therapy Products: Regulatory Perspective and Comparability Considerations. Korea NIFDS-USP joint workshop.
- 12/22 Update on Comparability in Manufacturing Cell and Gene Therapy Products. FDAnews webinar.
- 8/23 Overview of FDA Draft Guidance on Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products. CHI Bioprocessing Summit.
- 8/23 Technology Transfer for Cell and Gene Therapy Products. CHI Bioprocessing Summit.
- 8/23 Decentralized Manufacturing of Cell Therapy Products: Comparability Considerations. CHI Bioprocessing Summit.
- 8/23 - Regulatory Expectations for Potency Testing Development. Hanson Wade Gene Therapy Potency Testing conference.
- 11/23 Manufacturing Changes and Comparability for Cell and Gene Therapy Products. Hanson Wade Gene Therapy Analytical Development conference.
- 11/23 Applying Biologics Development Practices to Gene Therapy Products: Quality by Design. Hanson Wade Gene Therapy Analytical Development conference.
- 8/24 Effective CMC Due Diligence for Cell and Gene Therapy Products and Technology. CHI Bioprocessing Summit, Boston, MA.
- 8/24 US Regulatory Update 2024: New Guidance Documents from FDA OTP. CHI Bioprocessing Summit, Boston, MA.
- 10/24 Regulatory Considerations for Process Automation: Comparability to Bridge Process Changes. BioProcess Development Workshop - Automation in Cell Therapies: Common Pitfalls and How to Avoid Them. North Carolina Biotechnology Center, Durham, NC.
- 11/24 Localization and Technology Transfer of CAR-T Cell Therapies. Saudi FDA workshop.
- 11/24 Starting Materials Considerations for Cell and Gene Therapy Manufacturing. Charles River Laboratories webinar.

## Publications

1. Burger SR, and DC Blanchard. The persistence of air bubbles at a seawater surface. *J. Geophys. Res.* 1983;88:7724-26.
2. Burger SR. Two related works: Osler's *Aequanimitas* and Bernard's *An Introduction to the Study of Experimental Medicine*. *Pharos* 1985;48:6-8.
3. Burger SR, and JW Bennett. Droplet enrichment factors of pigmented and non-pigmented *Serratia marcescens*: possible selective function for prodigiosin. *Appl. Environ. Microbiol.* 1985;50:487-90.
4. Williams TM, L Eisenberg, JE Burlein, CA Norris, S Pancer, D Yao, SR Burger, M Kamoun, and JA Kant. Two regions within the human IL-2 gene promoter are important for inducible IL-2 expression. *J. Immunol.* 1988;141:662-66.
5. Spitalnik PF, JM Danley, SR Burger, and SL Spitalnik. The glycosphingolipid composition of the human hepatoma cell line, Hep-G2. *Arch. Biochem. Biophys.* 1989;273:578-91.
6. Burger SR, AT Remaley, RJ Muschel, M Kelsten, W Wunner, and SL Spitalnik. Stable expression of the rabies glycoprotein gene in mammalian cells – a model to study the regulation of protein glycosylation. *J. Gen. Virol.* 1991;72:359-67.
7. Remaley AT, M Ugorski, N Wu, L Litzsky, SR Burger, JS Moore, M Fukuda, and SL Spitalnik. Expression of human glycophorin A in wild-type and glycosylation-deficient Chinese hamster ovary cells. *J. Biol. Chem.* 1991;266:24176-83.
8. Burger SR, MM Zutter, S Sturgill-Koszycki, and SA Santoro. Induced cell surface expression of functional alpha<sub>2</sub>-beta<sub>1</sub> integrin during megakaryocytic differentiation of K562 leukemic cells. *Exp. Cell Res.* 1992;202:28-35.
9. Burger SR, BT Thomas, and JE Grishaber. Integration of concurrent collection of plasma into a plateletpheresis program. *J. Clin. Apheresis* 1994;9:126-29.
10. Spitzer G, DR Adkins, and SR Burger. 1994. Peripheral blood stem cells: Possibilities and limitations. In *Hematopoietic Stem Cells: Biology and Therapeutic Applications*, (D. Levitt and R. Mertelsmann, eds.). Marcel Dekker, Inc., New York, pp. 391-401.
11. Stroncek DF, SK Fautsch, SR Burger, JE Wagner, and J McCullough. Mislabeling of elutriation media: a demonstration of the need to improve the quality control of reagents produced for cell processing. *Transfusion* 1995;35:952-54.
12. Whitley CB, RS McIvor, EL Aronovich, SA Berry, BR Blazar, SR Burger, JH Kersey, RA King, AJ Faras, RE Latchaw, JJ McCullough, D Pan, NKC Ramsay, and DF Stroncek. Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II): human gene therapy protocol. *Human Gene Therapy* 1996;7:537-49.
13. Burger SR, BT Thomas, and JE Grishaber. 1996. Concurrent collection of plasma. In *Donor Recruitment: Strategies for Success* (C Mihalko and L Botos, eds.). AABB Press, Bethesda.

**Publications, continued**

14. Burger SR, SK Fautsch, DF Stroncek, and J McCullough. Concentration of citrate anticoagulant in peripheral blood stem cell collections. *Transfusion* 1996;36:798-801.
15. Verfaillie CM, R Bhatia, W Miller, F Mortari, V Roy, S Burger, J McCullough, K Stiegelbauer, G Dewald, S Heimfeld, JS Miller, PB McGlave. *BCR/ABL* negative primitive progenitors suitable for transplantation can be selected from most early chronic phase but not accelerated-phase chronic myelogenous leukemia patients. *Blood* 1996;87:4770-9.
16. Shankar R, C Whitley, D Pan, S Burger, J McCullough, D Stroncek. Retroviral transduction of peripheral blood leukocytes in a hollow fiber bioreactor. *Transfusion* 1997;37:685-90.
17. Burger SR, AH Hubel, J McCullough. Development of an infusible-grade solution for non-cryopreserved hematopoietic cell storage. *Cytotherapy* 1999;1:123-133.
18. Stroncek DF, A Hubel, RA Shankar, SR Burger, D Pan, J McCullough, CB Whitley. Retroviral transduction and expansion of peripheral blood lymphocytes for the treatment of mucopolysaccharidosis II, Hunter syndrome. *Transfusion* 1999;39:343-50.
19. Burger SR, DM Kadidlo, J McCullough. Improved progenitor assay standardization using peripheral blood progenitor cells from a donor treated with granulocyte-colony-stimulating factor. *Transfusion* 1999;39:451-56.
20. Burger SR. Design and operation of a cGMP cell engineering laboratory. *Cytotherapy* 2000;2:111-22.
21. Mascotti K, J McCullough, SR Burger. Hematopoietic progenitor cell viability measurement: trypan blue *versus* acridine orange/propidium iodide. *Transfusion* 2000;40:693-96.
22. Burger SR. 2001. Umbilical cord blood stem cells. In *Handbook of Transfusion Medicine*, (C.D. Hillyer, K.L. Hillyer, F.J. Strobl, L.C. Jeffries, and, L.E. Silberstein, eds.). Academic Press, San Diego.
23. Simpson MA, J Reiland, SR Burger, LT Furcht, AP Spicer, Jr., TR Oegema, JB McCarthy. Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. *J. Biol. Chem.* 2001;276:17949-57.
24. Orchard PJ, BR Blazar, S Burger, B Levine, L Basso, DMK Nelson, K Gordon, RS McIvor, JE Wagner, JS Miller. Clinical scale selection of anti-CD3/CD28 activated T cells following transduction with a retroviral vector expressing herpes simplex virus thymidine kinase and truncated nerve growth factor receptor. *Human Gene Therapy* 2002;13:979-88.
25. Schmid JL, J McCullough, SR Burger, A Hubel. Non-cryopreserved bone marrow storage in STM-Sav, an infusible-grade cell storage solution. *Cell Preservation Technology* 2002;1:45-51.
26. McKenna DH, Rupp C, Wagner J, McGlennen R, Hirsch B, Dolan M, Burger S, Hanson M, Jaszcz W, Nguyen PL. Increased lymphoblast-like cells following umbilical cord blood stem cell transplantation do not predict recurrent acute leukemia. *Leukemia* 2002;16:2171-2.

**Publications, continued**

27. Koenigbauer UF, SR Burger, J McCullough. Non-frozen preservation of umbilical cord blood. *Transfusion* 2002;42:1383-84.
28. Burger SR. Advanced cell and gene therapies: translational development and GMP production. *BioProcessing* 2002;1:19-23 (invited review).
29. Burger SR. GTP/GMP cell engineering for cell and gene therapies. *BioProcessing* 2003;2:66-69 (invited review).
30. Burger SR. Current regulatory issues in cell and tissue therapy. *Cytotherapy* 2003;5:289-298 (invited review).
31. Burger SR. Therapeutic cancer vaccines. *BioProcessing* 2003;2(4):16 (invited editorial).
32. Burger SR, DM Kadidlo, N Bostrom, PJ Orchard. Cellular engineering of HSV-tk-transduced, expanded T-lymphocytes for GVHD management. *Acta Haematologica* 2003;110:121-131 (invited review).
33. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR, Burger SR, Panoskaltis-Mortari A, Keever-Taylor CA, Zhang MJ, Miller JS. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. *Bone Marrow Transplant* 2003;32:177-86.
34. Burger SR. Cell and gene therapy - challenges and strategies for an emerging industry. *Cell & Gene Therapy* 2004;1:9-14 (invited review).
35. Prince HM, Wall DP, Stokes KH, Wood R, Burger SR, Coghlan P, Boyce N. Cell processing for clinical trials and commercial manufacture. *Cell & Gene Therapy* 2004;1:15-21.
36. Steward CG, Blair A, Moppett J, Clarke E, Virgo P, Lankester A, Burger SR, Sauer MG, Flanagan AM, Pamphilon DH, Orchard PJ. High peripheral blood progenitor cell counts enable autologous backup before stem cell transplantation for malignant infantile osteopetrosis. *Biol Blood Marrow Transplant* 2005;11:115-21.
37. Burger SR. 2009. Commercial manufacturing of cell therapy products: considering the options. In *World Stem Cell Report 2009*, (Bernard Siegel, ed.). Genetics Policy Institute, Wellington, FL.
38. Deans R, Gunter KC, Allsopp T, Bonyhadi M, Burger SR, Carpenter M, Clark T, Cox CS, Driscoll D, Field E, Huss R, Lardenoije R, Lodie TA, Mason C, Neubiser R, Rasko JE, Rowley J, Maziarz RT. A changing time: The International Society for Cellular Therapy embraces its industry members. *Cytotherapy* 2010;12:853-6.
39. Kao GS, Kim HT, Daley H, Ritz J, Burger SR, Kelley L, Vierra-Green C, Flesch S, Spellman S, Miller J, Confer D. Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. *Transfusion* 2011;51:137-47.
40. Brandenberger R, Burger S, Campbell A, Fong T, Lapinskas E, Rowley J. Cell Therapy Bioprocessing. *BioProcess International* 2011;9(S1):30-37.

**Publications, continued**

41. Carmen J, Burger SR, McCaman M, Rowley JA. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. *Regenerative Medicine* 2012;7(1):85-100.
42. Bravery CA, Carmen J, Fong T, Oprea W, Hoogendoorn KH, Woda J, Burger SR, Rowley JA, Bonyhadi ML, Van't Hof W. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. *Cytherapy* 2013;15(1):9-19.
43. Eaker S, Armant M, Brandwein H, Burger S, Campbell A, Carpenito C, Clarke D, Fong T, Karnieli O, Niss K, Van't Hof W, Wagey R. Guidance in developing commercializable autologous/patient-specific cell therapy manufacturing. *Stem Cells Translational Medicine* 2013;2(11):871-83.
44. Burger, SR. FDA resources for cell and gene therapy product development. 2015. *Cell & Gene Therapy Insights* 2015; 4(10), 983-994.
45. Aghayan HR, Arjmand B, Burger SR. 2016. GMP Facilities for Clinical Cell Therapy Product Manufacturing: A Brief Review of Requirements and Design Considerations. In *Perinatal Tissue-Derived Stem Cells*. Babak Arjmand, ed. Humana Press, Cham, 215-228.
46. Bravery CA, Robinson S, Burger SR. Making the grade: untangling the myths of raw materials used for the manufacture of cell- and gene-based medicinal products. *Cell & Gene Therapy Insights* 2018;4(3), 207-225.
47. Holmberg JA, Henry SM, Burnouf T, Devine D, Marschner S, Boothby TC, Burger SR, Chou ST, Custer B, Blumberg N, Siegel DL, Spitalnik SL. National Blood Foundation 2021 Research and Development summit: Discovery, innovation, and challenges in advancing blood and biotherapies. *Transfusion*. 2022;62(11), 2391-2404.
48. Janssen WE and Burger SR. Producing cell-based therapeutic products with lot-to-lot consistency from highly variable starting cell products. *Cell & Gene Therapy Insights* 2022;8(10), 1277–1281.
49. Janssen WE and Burger SR. The living cell supply chain: a product-specific, rational approach to management of cellular starting material donors and donations. *Cell & Gene Therapy Insights* 2022; 8(10), 1375–1379.
50. Janssen WE and Burger SR. Analytics for cell and gene therapy products in early development: points to consider before preparing an IND for a first-in-human clinical trial. *Cell & Gene Therapy Insights* 2024; 10(8), 1237–1245.

## Abstracts

1. Harpstead SD, MR Urbano, J Vincent, SR Burger, EM Hrabak, FB Dazzo. 1978. Bacteriophages which degrade the capsular polysaccharide of *Rhizobium trifolii*. American Society for Microbiology, Michigan branch, annual meeting.
2. Burger SR, JW Bennett. 1983. Possible selective function for prodigiosin, a secondary metabolite of *Serratia marcescens*. American Society for Microbiology, Annual Meeting Abstracts, p. 277.
3. Spitalnik SL, JM Danley, SR Burger, PF Spitalnik. 1988. Secretion of blood group P active glycolipids by the Hep-G2 human hepatoma cell line. *Glycoconjugate J.* 5:306.
4. Burger SR, RJ Muschel, W Wunner, SL Spitalnik. 1989. Stable expression of the rabies glycoprotein gene in mammalian cells: a model to study the regulation of protein glycosylation. Academy of Clinical Laboratory Physicians and Scientists, Stony Brook, NY.
5. Burger SR, RJ Muschel, M Kelsten, W Wunner, SL Spitalnik. 1989. Stable expression of the rabies glycoprotein gene in mammalian cells - a model to study the regulation of protein glycosylation. Gordon Conference on Glycoproteins and Glycolipids, Ventura, CA.
6. Burger SR, AT Remaley, RJ Muschel, M Kelsten, W Wunner, SL Spitalnik. 1989. Stable expression of the rabies glycoprotein gene in mammalian cells - a model to study the regulation of protein glycosylation. Proceedings of the Tenth International Symposium on Glycoconjugates, Jerusalem, Israel. Abstract 127.
7. Burger SR, SA Santoro. 1991. Changes in integrin expression accompanying induced differentiation of K562 cells. Academy of Clinical Laboratory Physicians and Scientists, Little Rock, AR.
8. Burger SR, BT Thomas, JE Grishaber. 1994. Concurrent collection of plasma. American Association of Blood Banks annual meeting. *Transfusion* 34:81S.
9. Burger SR, SK Fautsch, J McCullough. 1995. Factors affecting mononuclear cell recovery in an automated cell separation system. International Society for Hematotherapy and Graft Engineering annual meeting. *Journal of Hematotherapy* 4:220.
10. Burger SR, SK Fautsch, DF Stroncek, J McCullough. 1995. Concentration of citrate anticoagulant in peripheral blood stem cell collections. International Society for Hematotherapy and Graft Engineering annual meeting. *Journal of Hematotherapy* 4:225.
11. Verfaillie CM, R Bhatia, JS Miller, J McCullough, SR Burger, PB McGlave. 1995. Clinical scale selection and ex vivo expansion of BCR/ABL-negative CD34+/HLA-DR- cells from CML marrow suitable for transplantation. American Society of Hematology annual meeting. *Blood* 86:294a.
12. Burger SR, DF Stroncek, SK Fautsch, JE Wagner, J McCullough. 1995. Mislabeling of elutriation media results in cell loss during processing. American Society of Hematology annual meeting. *Blood* 86:981a.

**Abstracts, continued**

13. Stroncek DF, R Konz, S Burger, R McGlennen, H Noreen, J Wagner, J McCullough. 1995. Post-transfusion salvage of umbilical cord blood cell DNA for molecular phenotyping. American Society of Hematology annual meeting. Blood 86:991a.
14. Shankar RA, DF Stroncek, D Pan, S Burger, J McCullough, C Whitley. 1995. Expansion and transduction of peripheral blood leukocytes with retroviral vector using a hollow-fiber bioreactor. American Society of Hematology annual meeting. Blood 86:1005a.
15. Haley R, J McCullough, G Moroff, M Clay, S Burger, S Wagner, I Feller, R Davey. 1997. Peripheral blood progenitor cell freezing: four methods. International Society for Hematotherapy and Graft Engineering annual meeting. Journal of Hematotherapy 6:387.
16. Burger SR, D Kadidlo, A Hubel, C Whitley, D Stroncek, J McCullough. 1997. Serum-free expansion of transduced lymphocytes for gene therapy. American Association of Blood Banks annual meeting. Transfusion 37:80S.
17. Reiland J, JB McCarthy, SR Burger. 1997. E-selectin and  $\alpha 4$  integrin function in homing-like adhesion of KG-1a cells to activated endothelial monolayers. American Association of Blood Banks annual meeting. Transfusion 37:79S.
18. Burger SR, G Herr, A Hubel, J McCullough. 1997. Development of an infusible-grade hematopoietic cell storage solution. American Association of Blood Banks annual meeting. Transfusion 37:63S.
19. Burger SR, SK Fautsch, D Kadidlo, J McCullough. 1998. Standardization and control of the hematopoietic progenitor cell assay. International Society for Hematotherapy and Graft Engineering annual meeting. Journal of Hematotherapy 7:274.
20. Burger SR, D Kadidlo, P Brodsky, T Coburn, J McCullough. 1998. Development of a computer software system for graft engineering. International Society for Hematotherapy and Graft Engineering annual meeting. Journal of Hematotherapy 7:275.
21. Burger SR, D Kadidlo, J Wagner, J McCullough. 1998. Graft engineering for transplant at distant centers. International Society for Hematotherapy and Graft Engineering annual meeting. Journal of Hematotherapy 7:288.
22. Burger SR, A Hubel, J McCullough. 1998. Development of an infusible-grade hematopoietic cell storage solution II. International Society for Hematotherapy and Graft Engineering annual meeting. Journal of Hematotherapy 7:296.
23. Mascotti K, J McCullough, SR Burger. 1998. Cell viability measurement: trypan blue vs. acridine orange/propidium iodide. International Society for Hematotherapy and Graft Engineering annual meeting. Journal of Hematotherapy 7:296.
24. Burger SR, D Kadidlo, J Wagner, J McCullough. 1998. Graft engineering for transplant at distant centers. National Marrow Donor Program Council meeting.

**Abstracts, continued**

25. Burger SR, SK Fautsch, D Kadidlo, J McCullough. 1998. Standardization and control of the hematopoietic progenitor cell assay. National Marrow Donor Program Council meeting.
26. Burger SR, A Hubel, J McCullough. 1998. Development of an infusible-grade hematopoietic cell storage solution. National Marrow Donor Program Council meeting.
27. Heapy KM, J Reiland, JB McCarthy, SR Burger. 1998. Soluble factors from marrow stromal cells modulate marrow endothelial cell adhesive phenotype. American Association of Blood Banks annual meeting. *Transfusion* 38:95S.
28. Schmid J, J McCullough, SR Burger. 1998. Validation of an infusible-grade cell storage solution for bone marrow. American Association of Blood Banks annual meeting. *Transfusion* 38:95S.
29. Burger SR, D Kadidlo, P Brodsky, T Coburn, J McCullough. 1999. Development of a computer software system for graft engineering II. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 1:219.
30. Burger SR, D Kadidlo, and J McCullough. 1999. Clinical experience with T-lymphocyte depletion by counterflow elutriation. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 1:220.
31. Schmid J, J McCullough, SR Burger. 1999. Validation of an infusible-grade cell storage solution for bone marrow. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 1:220.
32. Heapy KM, J Reiland, JB McCarthy, SR Burger. 1999. Soluble factors from marrow stromal cells modulate marrow endothelial cell adhesive phenotype. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 1:243.
33. Haley NR, McCullough JJ, Moroff G, Burger S. 1999. A comparison of progenitor cell freezing methods at two years: is 10% dimethyl sulfoxide the best cryoprotectant? International Society for Experimental Hematology annual meeting.
34. Burger SR, Schierman T, Kadidlo D, Chrysler GR, Booher J, Clay ME, Herr G, McCullough J. 1999. Efficiency of post-cryopreservation umbilical cord blood progenitor cell recovery. American Association of Blood Banks annual meeting. *Transfusion* 39:101S.
35. Burger SR, Kadidlo D, McCullough J. 1999. Clinical experience with T-lymphocyte depletion by counterflow elutriation. American Association of Blood Banks annual meeting. *Transfusion* 39:102S.
36. Haley NR, McCullough JJ, Moroff G, Burger SR, Clay M. 1999. A comparison of progenitor cell freezing methods at two years: is 10% dimethyl sulfoxide (DMSO) in LN2 the best cryoprotectant? American Society of Hematology annual meeting. *Blood* 94:553a.

**Abstracts, continued**

37. Burger SR, Bostrom N, Kadidlo DM, Gordon K, Orchard P. Thymidine kinase transduction and expansion of allogeneic T-lymphocytes for management of graft-vs.-host disease. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 2:317, 2000.
38. Burger SR, Kadidlo DM, Fautsch S, Burns L, Weisdorf D, Miller JS. Activation and expansion of immune effector cells for post-transplant immunotherapy. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 2:317, 2000.
39. Goodell WM, Burger SR. 2000. Expression of the Stromal-Derived Factor-1 receptor CXCR4 on CD34+ cells as a function of hematopoietic recovery following bone marrow transplantation. International Society for Hematotherapy and Graft Engineering annual meeting.
40. Kruel K, Van Orsow E, Kadidlo DM, Burger SR. Product storage conditions to prevent cell clumping during CD34+ selection. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 2:343, 2000.
41. Bachowski GJ, Kadidlo DM, Burger SR. Evaluation of Gram-stained buffy-coat preparations for real-time detection of microbial contamination in engineered cell products. American Association of Blood Banks annual meeting, 2000.
42. Burger SR, Bostrom N, Kadidlo DM, Gordon K, Orchard P. Thymidine kinase transduction and expansion of allogeneic T-lymphocytes for management of graft-vs.-host disease. American Association of Blood Banks annual meeting, 2000.
43. Moppett J, Blair A, Clarke E, Virgo P, Pamphilon D, Lankester A, Burger SR, Orchard PJ, Steward CG. Peripheral blood: a rich source of progenitor cells in children with malignant infantile osteopetrosis (MIOP). American Society of Hematology annual meeting, 2000.
44. Burger SR, L Basso, NJ Bostrom, DM Kadidlo, P Orchard. Decreased culture duration, IL-2 concentration, and CD3/CD28-mediated activation enhances function of thymidine kinase-transduced, expanded T-cells. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 3:512, 2001.
45. Minster NI, KS Bailey, SM Reinacher, CE Smith, G Ishioka, J Fikes, NJ Bostrom, EA Van Orsow, DM Kadidlo and SR Burger. Development of an HLA-A2 peptide-pulsed dendritic cell tumor vaccine. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 3:535, 2001.
46. Bostrom NJ, SK Fautsch, DM Kadidlo, SR Burger, IJ Okazaki, JS Miller. Enzymatic and mechanical tumor cell dispersion for tumor vaccine production. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 3:534, 2001.
47. Kadidlo DM, K Kruel and SR Burger. Deviation management in a GMP cell engineering clinical laboratory. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 3:531, 2001.

**Abstracts, continued**

48. van Orsow EA, DM Kadidlo and SR Burger. Cell engineering in a GMP environment: the Fairview-University Medical Center experience. International Society for Hematotherapy and Graft Engineering annual meeting. *Cytotherapy* 3:531, 2001.
49. Orchard PJ, J Miller, L Basso, C Eide, DM Kadidlo, N Bostrom, SR Burger and J Wagner. Development of a successful clinical scale procedure for activation, transduction and selection of human T cells: factors affecting cellular function. American Society of Hematology annual meeting, 2001.
50. Burger, SR. Enabling commercialization of clinical cell and gene therapies - challenges and strategies. *Regenerate* 2004.
51. Beal J, M Herco, K Johnson, J Richards, M Endejann, A Mitchell, SR Burger, KB Johnson. Isolation and expansion of human skeletal muscle precursor cells: Process development and optimization. ISCT annual meeting, 2011.
52. Herco M, J Beal, K Johnson, J Richards, M Endejann, A Mitchell, SR Burger, KB Johnson. Extended stability study of a human skeletal muscle precursor cell therapy product using CryoStor10 and Hypothermosol-FRS. ISCT annual meeting, 2011.
53. Bayer RJ, P van der Wal, SR Burger, A Stock. Sourcing human blood-derived raw material: Optimization, qualification and control. ISCT annual meeting, 2011.
54. McPherson G, P van der Wal, D De Leonardis, SR Burger, A Stock. Sourcing human blood-derived raw material: Optimization, qualification and control. Society for Immunotherapy of Cancer (SITC) annual meeting, 2011.
55. Janssen WE, SR Burger. Variable in, variable out: Toward greater consistency in cell and gene therapy products. ISCT annual meeting, 2021.
56. Burger SR, WE Janssen. Effective CMC due diligence for cell and gene therapy products and technology. CHI Bioprocessing Summit, 2024.
57. Janssen WE, SR Burger. Knowing the end of the story while writing the beginning: Development of effective and durable cell and gene therapy CMC. CHI Bioprocessing Summit, 2024.
58. Kotanchiyev, S, R Hall, K Palla, L D’Lima, A Nguyen, SR Burger, WE Janssen. Cell mimics as high precision controls for CGT analytics and potency assays. ISCT annual meeting, 2025. *Cytotherapy* 27(5):S23-S24, 2025.